Mayo Foundation for Medical Education and Research

Unity Biotechnology, Inc.

Buck Institute for Research on Aging

The Johns Hopkins University

Buck Institute for Research Aging

Yi Zhu

James L Kirkland

Tamar Tchkonia

Nathaniel E David

Remi-Martin Laberge

Judith Campisi

Marco Demaria

Jan M A Van Deursen

Alain Philippe Vasserot

Darren J Baker

Bennett G Childs

Albert Davalos

Jennifer H Elisseeff

Chaekyu Kim

Okhee Jeon

Jordan D Miller

Allyson K Palmer

Nathan K LeBrasseur

Jan Ma Van Deursen

Jan MA Van Deursen

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Treating liver disease by selectively eliminating senescent cells

Provided herein are methods and uses for treatment or prophylaxis of a senescent cell associated disease or disorder by administering a senolytic combination comprising dasatinib and quercetin or an analog thereof to a subject in need thereof. In certain embodiments, the senescent cell associated disease or disorder is a cardiovascular disease or disorder, inflanunatory disease or disorder, a pulmonary disease or disorder, a neurological disease or disorder, or a metabolic disease or disorder.

Killing senescent cells and treating senescence-associated conditions using a SRC inhibitor and a flavonoid

Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue

Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor

Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye

Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss

Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase

Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. In advanced lesions, senescent cells promote features of plaque instability, including elastic fiber degradation and fibrous cap thinning, by heightening metalloprotease production. This invention provides methods and materials for treating arthritis by removing senescent cells in or around atherosclerotic plaques, thereby stabilizing the plaques, inhibiting rupture of the plaques and pathological sequelae that manifest as coronary artery disease.

Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques

Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells

Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen

Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population

This disclosure provides a technology for managing the sensation of pain in a subject in need thereof. Treatment methods according to this invention include administering to the subject a formulation that contains an effective amount of (4-[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone).

Treatment of joint pain

Treatment of ophthalmic conditions by selectively removing senescent cells from the eye

Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2

Use of sulfonamide inhibitors of Bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary disease

Growing community of inventors

Rochester, MN, United States of America

Yi Zhu